# Healthcare Global Enterprises share price today (Healthcare Global Enterprises Ltd, NSE: HCG)

> Healthcare Global Enterprises share price today: ₹611.65 at the NSE close on 3 November 2026, down 17.6% in a year. Healthcare Global Enterprises (NSE: HCG) is worth ₹9,125 crore, trades at a P/E of 188.9 and has closed between ₹527.70 and ₹754.93 over the past 52 weeks. > Healthcare Global Enterprises Ltd is reporting record margins. HCG · Hospitals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: ₹611.65 (−17.6% in a year)
- P/E: 188.9× (higher than 60% of the last 10 years)
- Revenue (Jun 2026): ₹695 Cr (+13.4% on a year ago)
- Profit (Jun 2026): ₹16.0 Cr (+166.7% on a year ago)
- Operating margin: 18.0% (flat on a year ago)
- ROCE: 8%, FY26
- Profit that came in as cash: 840%, last 3 years

The main question: the share price moved −17.6% in a year while yearly earnings per share moved −69.4%. The difference came from the market paying a higher multiple. ## What is the Healthcare Global Enterprises share price today? Healthcare Global Enterprises Ltd's share price was ₹611.65 at the close on 3 November 2026. It has been rising for 20 weeks. That is 4.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹528 and ₹755, and at that close it sat 37% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running. Over the last 11 years the share price moved +251% while the NIFTY 500 moved +243%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 1 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Healthcare Global Enterprises this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), profit grew again in the June 2026 quarter and foreign funds (FIIs) cut their stake for 4 quarters in a row. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹695 crore, +13.4% on a year earlier. Why: More patients came and the company earned more from people outside low margin government schemes. Many hospitals had their best ever quarter. Next results: check whether existing hospitals keep growing at the planned pace and new beds start earning. From the earnings call on 7 Aug 2026. 2. Profit grew again in the June 2026 quarter Profit was ₹16 crore, +166.7% on a year earlier (₹6 crore), after 2 quarters of decline. Why: Profit rose because dropping some low margin chemotherapy lifted the company's margin, so more of each rupee of sales became profit. From the earnings call on 7 Aug 2026. 3. Foreign funds (FIIs) cut their stake for 4 quarters in a row From 3.6% to 2.7% of the company by the September 2026 quarter. ## What are Healthcare Global Enterprises' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Healthcare Global Enterprises reported revenue of ₹695 crore, up 13.4% from ₹613 crore a year earlier, and a profit of ₹16.0 crore, up 166.7% from ₹6.00 crore. ### Healthcare Global Enterprises results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹695 crore | ₹613 crore | +13.4% |
| Profit | ₹16.0 crore | ₹6.00 crore | +166.7% |
| Earnings per share | ₹0.92 | ₹0.32 | +187.5% |
| Operating margin | 18.0% | 18.0% | 0.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Healthcare Global Enterprises' management discussed these results on a call held on 7 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Healthcare Global Enterprises share price history? Healthcare Global Enterprises closed at ₹611.65 on 3 November 2026, down 17.6% from ₹742.56 a year earlier (31 October 2025) and up 154.9% over five years. Its highest weekly close since April 2016 was ₹754.93 on 7 November 2025. ### Healthcare Global Enterprises share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹549.65 | +11.3% |
| 1 month ago · 1 Oct 2026 | ₹668.75 | −8.5% |
| 6 months ago · 30 Apr 2026 | ₹572.55 | +6.8% |
| 1 year ago · 31 Oct 2025 | ₹742.56 | −17.6% |
| 3 years ago · 3 Nov 2023 | ₹372.94 | +64.0% |
| 5 years ago · 4 Nov 2021 | ₹239.92 | +154.9% |
| 10 years ago · 4 Nov 2016 | ₹247.32 | +147.3% |
| Earliest weekly close in our records · 1 Apr 2016 | ₹174.02 | +251.5% |
| Highest weekly close since April 2016, also the 52-week high · 7 Nov 2025 | ₹754.93 | −19.0% |
| Lowest weekly close since April 2016 · 17 Apr 2020 | ₹69.02 | +786.2% |
| 52-week low (weekly close) · 2 Apr 2026 | ₹527.70 | +15.9% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (560 weekly closes from 1 April 2016 to 3 November 2026.)

## What is the latest news on Healthcare Global Enterprises? 3 Nov 2026: Healthcare Global Enterprises closed at ₹611.65, up 11.3% on the week and down 8.5% on the month. 7 Aug 2026: Healthcare Global Enterprises held its results call for April to June 2026. Management guided: Mid-teens revenue growth from existing centres plus greenfield and brownfield expansions. ### Earlier

- Results for April to June 2026: Revenue up 13.4% and profit up 166.7% on a year earlier. ## What dividend does Healthcare Global Enterprises pay? Healthcare Global Enterprises has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Healthcare Global Enterprises Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Healthcare Global Enterprises management say on the latest results call? On the call for April to June 2026, held on 7 August 2026, Healthcare Global Enterprises' management guided: Mid-teens revenue growth from existing centres plus greenfield and brownfield expansions. > “Over the next 2 years, we are looking at a 21-22% EBITDA margin. Over the next 4 to 5 years, we are confident of exceeding the 25% margin level.”
> Management, on the call for April to June 2026

### What management guided

- Consolidated operating margin 21-22% over the next 2 years. - Consolidated operating margin above 25% over the next 4-5 years. - Additional operational beds: 65 in FY27, 520 in FY28-FY29 and 230 in FY30; nearly 60% brownfield and three greenfield projects. - North Bangalore monthly break-even during FY27 and optimal utilization of 60-65% within 3-4 years. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/5759/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 7 August 2026.)

## What to watch in Healthcare Global Enterprises' next results? When Healthcare Global Enterprises reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: North Bangalore to hit the stated monthly break-even goal; track clinician ramp-up, insurance empanelments and catchment awareness. - What to check (from the call)
- North Bangalore to hit the stated monthly break-even goal; track clinician ramp-up, insurance empanelments and catchment awareness. - Margin progression to remain driven by payer mix and clinical complexity; check low-margin chemotherapy replacement and new-hospital loss absorption. - Capacity rollout and growth or maintenance spend to track the planned programme; verify commissioning after annual utilization assessments. - ESOP charge to hit Q2 P&L; confirm magnitude and accounting treatment. ## Which stock lists is Healthcare Global Enterprises on? Healthcare Global Enterprises is not on any of our India lists this week. ## Is Healthcare Global Enterprises profitable? Healthcare Global Enterprises Ltd earned ₹16.0 Cr of net profit in the Jun 2026 quarter, +166.7% on the same quarter a year earlier. Full-year FY26 profit was ₹23.0 Cr. Over 10 years profit has grown 27.7% a year on average. That is 2.3% of the quarter's revenue. The same quarter a year earlier earned ₹6.0 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹23.0 Cr (−53.1% on the year before). Why profit moved: revenue changed +13.4% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −19.1% and revenue +13.7%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Healthcare Global Enterprises make, and is it growing? Healthcare Global Enterprises Ltd reported ₹695 Cr of revenue in the Jun 2026 quarter, +13.4% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 10 years it has grown 15.8% a year on average. The last full year, FY26, came in at ₹2,538 Cr. The last four reported quarters add to ₹2,627 Cr. FY26 revenue was ₹2,538 Cr, +14.4% on the year before. Recent pace: the last four quarters grew +13.7% on average, against 15.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +13.7%, against +15.2% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −21.4%, against −19.6% a year (stabilising). ## How much of every ₹100 of sales does Healthcare Global Enterprises keep? Healthcare Global Enterprises Ltd's operating margin was 18.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 9.0% and 18.0%. The latest quarter is within that range. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed +0.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Healthcare Global Enterprises' profit turning into cash? Over the last 3 years, 840% of Healthcare Global Enterprises Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹347 Cr of operating cash against ₹23.0 Cr of profit. After ₹258 Cr of spending on assets, ₹89.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 840% of profit came in as cash: the cash cycle got 28 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 2.4× depreciation over three years. The next section checks what that spending is building. ## Where does Healthcare Global Enterprises' cash go? Healthcare Global Enterprises Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −93 days in FY26, up from −121 days in FY21. It spent ₹1,539 Cr on assets over the last 3 years. Customers take 60 days to pay, and stock sits for 32 days on average. At FY26 sales of ₹2,538 Cr, each day of that cycle ties up about ₹7.0 Cr, so roughly −₹647 Cr is tied up in the business at any time. FY26: customers took 60 days to pay and stock sat for 32 days, about 1.1 months of sales sitting as stock, for a full cycle of −93 days, longer than FY21's −121. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 32 days. Customers pay about 60 days after that. Suppliers are paid at 185 days. Together that makes the −93-day cycle. Spending on assets: ₹1,539 Cr over the last 3 years, against ₹629 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹19.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Healthcare Global Enterprises' P/E ratio, and how does it compare with its own history? Healthcare Global Enterprises Ltd's P/E is 188.9×, in the middle of its own history: higher than 60% of past readings. Its usual P/E (the middle reading) is 160.9×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −69.4% while the price moved −17.6%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 10 years the price moved +9.5% a year; about +12.4% a year came from earnings growth and about −2.9 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 78% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Healthcare Global Enterprises business getting better or worse? Healthcare Global Enterprises Ltd's business is turning around. Profit growth has swung from −54.0% at its low to −21.4%, rising from a low 1 quarters ago, with ROCE steady at 8.0%. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Healthcare Global Enterprises earn on its capital? Healthcare Global Enterprises Ltd earned a ROCE of 8% in FY26. That is up from a low of −1% in FY21. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 0.9% net margin and 0.65× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 0.9% net margin × 0.65× asset turnover × 2.94× leverage (assets divided by equity) ≈ 1.7% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 78% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Healthcare Global Enterprises have too much debt? Healthcare Global Enterprises Ltd had ₹1,735 Cr of borrowings against ₹1,332 Cr of equity in FY26, so its debt is 1.30× its equity. Its operating profit is 3 times its interest bill. Over 5 years borrowings went from ₹977 Cr to ₹1,735 Cr. Over the last 3 of those years it spent ₹1,539 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 78% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Healthcare Global Enterprises shareholding pattern? Domestic institutions raised their stake in Healthcare Global Enterprises Ltd by 9.1 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 20.8% of the company. Promoters moved −7.0 points over the same period, to 64.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +9.1 points over 8 quarters, to 20.8%; Promoters: −7.0 points over 8 quarters, to 64.2%; Foreign institutions: −1.6 points over 8 quarters, to 2.7%. Why the owners changed: foreign institutions moved −1.6 points and domestic institutions +9.1 points over 8 quarters, while promoters moved −7.0 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Healthcare Global Enterprises from balance-sheet trouble? For Healthcare Global Enterprises Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Healthcare Global Enterprises rank in its industry? 31.1 out of 100, rank 19 of 20 in Hospitals, with 71% of the evidence available. Healthcare Global Enterprises Ltd scores 31.1 out of 100 against the 20 companies it is compared with in Hospitals, ranking 19. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 11.7 + 6.4 + 8.5 + 4.5 = 31.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Healthcare Global Enterprises compared with? Healthcare Global Enterprises ranks 19 of 20 Hospitals companies on the 4-Factor Sector Score, with 31.1 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Sector-leading setup · 81% evidence 80.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 35.1% · Profit 100% · Operating margin change 6 points · 88% evidence Capital efficiency 23.1/25 · ROCE 26.2% · Operating margin 31% · 100% evidence Valuation 14.1/20 · P/E 43.4× · PEG 0.68 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 45.6% · 1 year 115.4% · 25% evidence · 5 of 5 weeks ahead Exact sum: 31 + 23.1 + 14.1 + 12.5 = 80.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 100% evidence 68.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.5/25 · ROCE 12.4% · Operating margin 28% · 100% evidence Valuation 11.1/20 · P/E 49× · PEG 1.05 · 100% evidence Relative strength 13.8/20 · Lead over its industry 41.8% · Lead over NIFTY 500 45.4% · 1 year 161.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.5 + 11.5 + 11.1 + 13.8 = 68.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · turning · Most evidence points up · 78% evidence 68.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 17.2% · Profit 33.2% · Operating margin change 1 points · 83% evidence Capital efficiency 15.2/25 · ROCE 17.4% · Operating margin 16% · 76% evidence Valuation 12.7/20 · P/E 57.7× · PEG n/a · 50% evidence Relative strength 16.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 11.2% · 1 year 10% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24 + 15.2 + 12.7 + 16.6 = 68.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dr Agarwals Eye Hospital Ltd](https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd) DRAGARWQ · breaking out · Evidence leans up · 81% evidence 62.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.4/25 · ROCE 17.2% · Operating margin 30% · 100% evidence Valuation 12.5/20 · P/E 33.7× · PEG 1.36 · 100% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 9.2% · 1 year 0.8% · 25% evidence · 8 of 12 weeks ahead Exact sum: 21.1 + 17.4 + 12.5 + 11.6 = 62.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · breaking out · Evidence leans up · 96% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 15% · Profit 15.8% · Operating margin change 1 points · 88% evidence Capital efficiency 19.1/25 · ROCE 22.6% · Operating margin 29% · 100% evidence Valuation 8.9/20 · P/E 24.8× · PEG 2.01 · 100% evidence Relative strength 14.7/20 · Lead over its industry 1.9% · Lead over NIFTY 500 6.6% · 1 year -9.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.8 + 19.1 + 8.9 + 14.7 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.4/35 · Revenue 18% · Profit 0% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 19.9% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 23× · PEG 0.94 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.1% · 1 year -10.7% · 25% evidence · 4 of 12 weeks ahead Exact sum: 15.4 + 18.2 + 18.5 + 9.1 = 61.2 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 78% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 43.9% · Profit 22.5% · Operating margin change -2 points · 83% evidence Capital efficiency 12.4/25 · ROCE 12.9% · Operating margin 23% · 76% evidence Valuation 6.7/20 · P/E 49.3× · PEG n/a · 50% evidence Relative strength 19.1/20 · Lead over its industry 17.1% · Lead over NIFTY 500 21.6% · 1 year 16.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.4 + 12.4 + 6.7 + 19.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · leader · Evidence leans up · 100% evidence 56.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.8/25 · ROCE 14.6% · Operating margin 18% · 100% evidence Valuation 8.0/20 · P/E 39.7× · PEG 2.44 · 100% evidence Relative strength 16.7/20 · Lead over its industry 8.4% · Lead over NIFTY 500 12.9% · 1 year 18.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 12.8 + 8 + 16.7 = 56.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans up · 85% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 10.8% · Profit 10.9% · Operating margin change 0 points · 100% evidence Capital efficiency 17.6/25 · ROCE 35.8% · Operating margin 19% · 100% evidence Valuation 13.2/20 · P/E 14.6× · PEG 1.47 · 100% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -49.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 17.6 + 13.2 + 7.7 = 51.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 10. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · losing its lead · Evidence leans up · 96% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 21.3% · Profit 3.4% · Operating margin change -2 points · 88% evidence Capital efficiency 17.3/25 · ROCE 17.4% · Operating margin 22% · 100% evidence Valuation 5.5/20 · P/E 59.7× · PEG 9.11 · 100% evidence Relative strength 14.2/20 · Lead over its industry 3.7% · Lead over NIFTY 500 8.1% · 1 year -3.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.5 + 17.3 + 5.5 + 14.2 = 50.5 · What this means: Relative strength against the index is 8.1%, and revenue and profit growth are weak. 11. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 50.3 out of 100 Growth Capital Valuation Relative
12. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · quiet · Evidence leans down · 85% evidence 48.7 out of 100 Growth Capital Valuation Relative
13. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · basing · Evidence leans down · 78% evidence 45.1 out of 100 Growth Capital Valuation Relative
14. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 63% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · quiet · Evidence leans down · 78% evidence 40.8 out of 100 Growth Capital Valuation Relative
16. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 96% evidence 35.2 out of 100 Growth Capital Valuation Relative
17. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 78% evidence 34.8 out of 100 Growth Capital Valuation Relative
18. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Most evidence points down · 100% evidence 33.0 out of 100 Growth Capital Valuation Relative
19. Healthcare Global Enterprises Ltd this page HCG · quiet · Most evidence points down · 71% evidence 31.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.7/35 · Revenue 13.7% · Profit -21.4% · Operating margin change 0 points · 83% evidence Capital efficiency 6.4/25 · ROCE 8.3% · Operating margin 18% · 76% evidence Valuation 8.5/20 · P/E 181× · PEG n/a · 15% evidence Relative strength 4.5/20 · Lead over its industry -7.5% · Lead over NIFTY 500 -3.3% · 1 year -21.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 11.7 + 6.4 + 8.5 + 4.5 = 31.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 38% evidence 42.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to Healthcare Global Enterprises in size? Healthcare Global Enterprises is the 11th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Krishna Institute of Medical Sciences, Rainbow Childrens Medicare and Yatharth Hospital & Trauma Care Services. Just below it: Jupiter Life Line Hospitals, Kovai Medical Center & Hospital and Artemis Medicare Services. ### Hospitals companies close in size

1. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) ₹29,476 crore
2. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) ₹12,378 crore
3. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) ₹8,931 crore
4. Healthcare Global Enterprises Ltd ₹8,742 crore
5. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) ₹8,430 crore
6. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) ₹6,363 crore
7. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ₹4,642 crore

[All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies)

### Companies close in size in other industries

1. [KEC International Ltd](https://www.sectoralpha.in/stocks/kec-international-ltd) ₹8,775 crore · Power - Transmission/Equipment
2. [Indo Count Industries Ltd](https://www.sectoralpha.in/stocks/indo-count-industries-ltd) ₹8,756 crore · Textiles - Home Textile
3. Healthcare Global Enterprises Ltd ₹8,742 crore
4. [Jaiprakash Power Ventures Ltd](https://www.sectoralpha.in/stocks/jaiprakash-power-ventures-ltd) ₹8,718 crore · Power - Generation/Distribution
5. [JK Tyre & Industries Ltd](https://www.sectoralpha.in/stocks/jk-tyre-industries-ltd) ₹8,701 crore · Tyres & Tubes

## What else do people ask about Healthcare Global Enterprises? ### What is Healthcare Global Enterprises's share price today? Healthcare Global Enterprises Ltd's share price is ₹611.65, −17.6% over the past year. The whole company is worth ₹9,125 Cr on the market. In the last 52 weeks it traded between ₹528 to ₹755; today it is 37% of the way up from the low, 4.3% below its 200-day average (as of 3 November 2026). ### What were Healthcare Global Enterprises's latest quarterly results? Healthcare Global Enterprises Ltd reported revenue of ₹695 Cr and net profit of ₹16.0 Cr for the Jun 2026 quarter. Revenue rose 13.4% and profit rose 166.7% compared with a year earlier. Earnings per share were ₹0.92. The operating margin was 18.0%, 0.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Healthcare Global Enterprises's market cap? Healthcare Global Enterprises Ltd's market capitalisation is ₹9,125 Cr at a share price of ₹611.65. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Healthcare Global Enterprises performing? Healthcare Global Enterprises Ltd's share price has been rising for 20 weeks. In its latest quarter, revenue rose 13.4% and profit rose 166.7% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 5 weeks running (as of 3 November 2026). ### Will Healthcare Global Enterprises's share price go up? This page does not forecast Healthcare Global Enterprises Ltd's share price. What it shows instead: the share price is ₹611.65, and it has been rising for 20 weeks. Its P/E of 188.9× is higher than 60% of its own last 10 years (as of 3 November 2026). ### Who owns Healthcare Global Enterprises? Promoters own 64.2% of Healthcare Global Enterprises Ltd, foreign institutions 2.7%, domestic institutions 20.8% and the public 12.3% (latest quarter). The biggest change over the last two years: Domestic institutions raised their stake by 9.1 percentage points over 8 quarters (as of 3 November 2026). ### Where is Healthcare Global Enterprises in its business cycle? Healthcare Global Enterprises Ltd's FY26 operating margin was 18.0%, against a 13-year range of 9.0% to 18.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 18.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Healthcare Global Enterprises story? The main question: the share price moved −17.6% in a year while yearly earnings per share moved −69.4%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Healthcare Global Enterprises a stock worth studying right now? What the numbers show: Healthcare Global Enterprises Ltd is reporting record margins. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Healthcare Global Enterprises share price forecast for 2026? What management itself guided: Mid-teens revenue growth from existing centres plus greenfield and brownfield expansions. This is research, not advice. We’re not SEBI-registered.